Chennai-based Caplin Point Laboratories has allocated ₹500-550 crore for capex, incl. expanding existing capacities, additional manufacturing sites & backward integration. It has completed expansion activities in Q4FY23 & ongoing projects in TN, AP & Puducherry. Q1FY24 saw 21% y-o-y growth in net pr…

Caplin Point working on ₹550-crore capex expansion

Caplin Point Labs earns spot on Forbes Asia’s “200 Best Under a Billion” list for 2023. Evaluating 20,000+ Asia-Pacific companies, the list honors those with annual sales under $1B. Criteria included debt mgmt, sales growth, EPS performance, and ROE. Shares down 3.25% to ₹1,028.

Caplin Point secures spot on Forbes list of ‘200 Best Under a Billion’

Caplin Point Laboratories has reported a 21 per cent year-on-year growth in its consolidated net profit for the first quarter at ₹104 crore

Caplin Point Q1 net profit jumps 21% to ₹104 crore

Caplin Point Labs’ subsidiary Caplin Steriles Ltd has approved setting up of a wholly-owned US-based subsidiary, Caplin Steriles USA Inc. It will have an initial share capital of $5,00,000 and cater to regulated markets like US & Europe for injectable & ophthalmic products. Caplin Steriles USA Inc w…

Caplin Point to set up step-down subsidiary to focus on US market

Caplin Point said the capex outlay includes expansion of Phase 2 & 3 projects of Caplin Steriles

Caplin Point chalks ₹350 crore capex for expansion

Shares of Caplin Point were trading at ₹754.60 apiece on NSE against the previous day’s closing price of ₹747.60 per share.

USFDA issues four observations on Caplin Point subsidiary’s injectable unit

Caplin Point Laboratories has announced that its revenue crossed ₹1,500-crore milestone in FY23. The Chennai-based pharmaceutical company recorded a consolidated total revenue of ₹1,523 crore in the financial year ended March 31, 2023, a 16 per cent year-on-year growth over ₹1,308 crore in FY22.

Caplin Point crosses ₹1,500-crore revenue milestone in FY23

So far this calendar year (CY23), shares of Caplin Point have declined 0.4 per cent, as against 1 per cent rise in the S&P BSE Sensex

Caplin Point rises 10% after arm gets USFDA nod for anti-inflammatory drug

We zoom in on the prospects of Indian Energy Exchange (IEX), as also the prospects of two other stocks — Biocon and Caplin Point Laboratories

IEX, Biocon, Caplin Point stocks: Here’s what technical charts suggest

Aarti Drugs Ltd, MAS Financial Services Ltd, Cochin Shipyard Ltd and Brightcom Group Ltd are among the other gainers in the BSE’s ‘A’ group today, 20 March 2023.